Plant · Scientific monograph
Matricaria chamomilla
German chamomile
For educational and scientific research only. Not medical advice. Independently verify claims against the cited primary sources. Consult a qualified healthcare professional before using any plant or fungal preparation.
Research areas: Inflammatory Pathways, Stress & Anxiety Research, Smooth Muscle Research, Tissue Repair Research
Research overview
Historical use
Chamomile (Matricaria chamomilla) is one of the oldest and most widely used medicinal herbs in European traditional medicine, with documented use dating to ancient Egypt and classical antiquity. Hippocrates, Dioscorides, and Asclepius all described its therapeutic applications. It has been used across cultures for GI complaints, skin conditions, inflammation, anxiety, and insomnia, and it remains listed in the pharmacopoeias of 26 countries.
Modern research context
German chamomile holds a broad evidence base across multiple therapeutic domains. A triple-blind RCT demonstrates efficacy in managing menopausal symptoms, though use requires caution due to associated side effects warranting further optimisation [3]. A 2025 randomised double-blind controlled trial confirms topical chamomile oil as a safe adjunctive intervention for diabetic neuropathy, producing statistically significant improvements in neuropathy indices [4]. A clinical trial evaluating chamomile oral solution alongside paclitaxel chemotherapy found improved sleep quality in cancer patients [5]. Meta-analysis supports benefits in PCOS for clinical and hormonal parameters [6].
Adverse effects
Generally well tolerated. Allergic reactions — including anaphylaxis — are the most clinically significant risk, particularly in individuals sensitised to Asteraceae/Compositae (ragweed, chrysanthemum, marigold). Contact dermatitis with topical formulations. GI upset at high oral doses. Rare: uterotonic effects. The 2025 menopausal trial noted associated side effects requiring further characterisation [3].
Contraindications
Contraindicated in patients with known allergy to Asteraceae plants. Avoid with warfarin — apigenin inhibits platelet aggregation and may potentiate anticoagulation. Caution with CYP3A4-metabolised drugs given documented CYP3A induction [1, 2]. Avoid in pregnancy due to potential uterotonic activity. Caution with CNS depressants due to additive sedation.
Clinical and phytochemical data
Used part
Dried flower heads; essential oil (steam-distilled); hydroethanolic extracts
Primary active compounds
Apigenin (flavone — primary bioactive)
Apigenin-7-glucoside
Chamazulene (from essential oil — anti-inflammatory)
Alpha-bisabolol and bisabolol oxides
Matricine (precursor to chamazulene)
Quercetin and luteolin (flavonoids)
Spiroethers (cis/trans-en-yn-dicycloether)
Mechanism of action
Apigenin, the principal flavone aglycone, is a partial agonist at GABA-A receptors (benzodiazepine-binding site), producing anxiolytic and mild sedative effects without significant tolerance development. Chamazulene and alpha-bisabolol potently inhibit COX-1, COX-2, and 5-lipoxygenase (5-LOX), suppressing prostaglandin and leukotriene synthesis and explaining the anti-inflammatory and spasmolytic effects [4]. Apigenin modulates aryl hydrocarbon receptor (AhR) signalling, with emerging evidence for neuroinflammatory pathway modulation relevant to dementia therapy. Matricaria chamomilla extract induces hepatic CYP3A expression through upregulation of the circadian clock protein BMAL1 in liver nuclei [1], with potential consequences for drug metabolism timing and magnitude.
Pharmacokinetics
Absorption
No human pharmacokinetic data are available for this species. The following is derived from preclinical animal studies and in vitro data only, and may not reflect human pharmacology. — Apigenin-7-glucoside is hydrolysed by intestinal glucosidases to the aglycone apigenin prior to absorption. Apigenin bioavailability is limited by poor aqueous solubility; food co-ingestion and lipid-based formulations improve absorption. Topical chamomile oil shows significant transcutaneous absorption, producing measurable systemic exposure in clinical settings [4].
Distribution
No human pharmacokinetic data are available for this species. The following is derived from preclinical animal studies and in vitro data only, and may not reflect human pharmacology. — Apigenin is extensively protein-bound (>99%) in plasma and distributes to CNS, skin, and reproductive tissues based on pharmacodynamic evidence from clinical trials [3, 6]. The highly lipophilic chamazulene distributes readily to inflamed tissues.
Metabolism
No human pharmacokinetic data are available for this species. The following is derived from preclinical animal studies and in vitro data only, and may not reflect human pharmacology. — German chamomile induces hepatic CYP3A expression via the BMAL1 circadian mechanism, as directly demonstrated in liver nuclei [1]. This induction may reduce plasma levels of co-administered CYP3A4 substrates. Phase II metabolism involves glucuronidation and sulfation of apigenin aglycone by UGT and SULT enzymes.
Excretion
No human pharmacokinetic data are available for this species. The following is derived from preclinical animal studies and in vitro data only, and may not reflect human pharmacology. — Apigenin glucuronide and sulfate conjugates are excreted renally. Chamazulene and bisabolol are eliminated via renal and biliary routes. Elimination half-life of apigenin in humans has not been characterised in available literature.
Safety and interactions
Drug interactions
CYP3A4 substrates: German chamomile directly induces CYP3A expression in liver nuclei through a BMAL1-dependent mechanism [1], potentially lowering plasma levels of CYP3A4-metabolised drugs (statins, immunosuppressants, benzodiazepines, HIV antiretrovirals). The clinical magnitude is time-of-day dependent given the circadian regulation [1]. Anticoagulants (warfarin): Apigenin inhibits platelet aggregation; additive bleeding risk with anticoagulants requires monitoring [2]. Herb-drug interactions via CYP450 enzyme modulation are documented as a general class concern [2].
Toxicity
Anaphylaxis is the most serious documented adverse event; risk is highest in Asteraceae-allergic individuals. In the paclitaxel chemotherapy trial, chamomile was well tolerated and did not worsen neuropathy [5]. The menopausal clinical trial noted side effects requiring characterisation [3]. No hepatotoxicity reports at standard oral doses. Essential oil should not be used undiluted on skin due to risk of irritation. Oral essential oil ingestion is not recommended.
Special precautions
Pregnancy
Potential uterotonic activity. Avoid oral chamomile preparations during pregnancy; topical use in limited areas is generally considered low-risk.
Lactation
Insufficient human safety data. Small amounts excreted in breast milk possible. Use with caution.
Hepatic impairment
CYP3A induction [1] may be attenuated in hepatic impairment, reducing drug interaction risk but also reducing therapeutic metabolite production. Monitor accordingly.
Renal impairment
Flavonoid conjugates renally excreted. Accumulation possible in severe renal impairment; use with caution.
Sources and references
- [1] - Ikeda M, Tsurudome Y, Enrin M et al., "German Chamomile (Matricaria chamomilla) Induces Cytochrome P450 Expression Through Increased BMAL1 Protein Expression in Liver Nuclei", Biochemical Genetics, 2025, PMID: 41091411
- [2] - Bukowska B, Grzegorowska A, Szczerkowska-Majchrzak E et al., "Hazardous Interactions Between Food, Herbs, and Drugs in the First Stage of Biotransformation: Case Reports of Adverse Drug Interactions in Humans", International Journal of Molecular Sciences, 2025, PMID: 40507996
- [3] - Mohsenzadeh-Ledari F, Agajani Delavar M, Moghadamnia AA et al., "Efficacy and safety of Matricaria chamomilla intervention in managing menopausal symptoms: a triple-blind clinical trial", Menopause, 2025, PMID: 39836709
- [4] - Amiri M, Imani MH, Imani AH et al., "Topical chamomile oil as a novel therapeutic intervention for diabetic neuropathy: A randomized double-blind controlled clinical trial", Explore, 2025, PMID: 40440968
- [5] - Nikkhah N, Karbasforooshan H, Shahid Sales S et al., "Evaluation of the protective effect of chamomile oral solution on the incidence of neurotoxicity caused by paclitaxel in breast cancer patients", Anti-Cancer Drugs, 2026, PMID: 41538720
- [6] - Firoozi Z, Molani-Gol R, Ebrahimzadeh-Attari V, Malek-Mahdavi A, "Evaluating Potential Effects of Chamomile (Matricaria chamomilla L.) in Polycystic Ovary Syndrome: A Systematic Review and Meta-Analysis", Food Science & Nutrition, 2026, PMID: 41767834
- [7] - Cabral MAL, Leal KCDS, Dos Santos JJS et al., "Effect of aromatherapy with Matricaria chamomilla in pain and anxiety management in hospital settings: A scoping review protocol", PLOS ONE, 2026, PMID: 41490312
- [8] - Arabi V, Sasanfar B, Darand M et al., "The association between medicinal herbs consumption and body weight and composition: a hospital based cross-sectional study", Scientific Reports, 2026, PMID: 41775830